1. Executive Summary
2. Research Methodology
3. Blood Preparation
3.1 Overview
3.2 Blood Components
3.2.1 RBC
3.2.2 Cryoprecipitated Anti-hemophilic Factor
3.2.3 Fresh Frozen Plasma
3.2.4 Platelets
3.2.5 Granulocytes
3.3 Blood Component Separation
3.3.1 PRP Method
3.3.2 Buffy Coat Method
4. Market Analysis
4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Products
4.2.2 Market Share by Type
4.2.3 Market Share by Application
4.2.4 Market Share by Region
5. Market Segmentation
5.1 Products
5.1.1 Whole Blood
5.1.1.1 Overview
5.1.1.2 Market Sizing (Actual & Forecasted)
5.1.2 Blood Derivatives
5.1.2.1 Overview
5.1.2.2 Market Sizing (Actual & Forecasted)
5.1.3 Blood Components
5.1.3.1 Overview
5.1.3.2 Market Sizing (Actual & Forecasted)
5.2 By Type
5.2.1 Platelet Aggregation Inhibitor
5.2.1.1 Overview
5.2.1.2 Market Sizing (Actual & Forecasted)
5.2.2 Fibrinolytic (Thrombolytic)
5.2.2.1 Overview
5.2.2.2 Market Sizing (Actual & Forecasted)
5.2.3 Anticoagulants
5.2.3.1 Overview
5.2.3.2 Market Sizing (Actual & Forecasted)
5.3 By Application
5.3.1 Thrombocytosis
5.3.1.1 Overview
5.3.1.2 Market Sizing (Actual & Forecasted)
5.3.2 Angina Blood Vessel Complications
5.3.2.1 Overview
5.3.2.2 Market Sizing (Actual & Forecasted)
5.3.3 Pulmonary Embolism
5.3.3.1 Overview
5.3.3.2 Market Sizing (Actual & Forecasted)
5.3.4 Renal Impairment
5.3.4.1 Overview
5.3.4.2 Market Sizing (Actual & Forecasted)
6. Regional Analysis
6.1 North America
6.1.1 Market Sizing (Actual & Forecasted)
6.1.2 The US
6.1.2.1 Market Sizing (Actual & Forecasted)
6.1.2.2 Market Share by Product
6.2 Europe
6.2.1 Market Sizing (Actual & Forecasted)
6.2.2 Market Share by Nations
6.2.3 Germany
6.2.3.1 Market Sizing (Actual & Forecasted)
6.2.4 France
6.2.4.1 Market Sizing (Actual & Forecasted)
6.3 Asia Pacific
6.3.1 Market Sizing (Actual & Forecasted)
6.3.2 Japan
6.3.2.1 Market Sizing (Actual & Forecasted)
6.3.3 China
6.3.3.1 Market Sizing (Actual & Forecasted)
6.3.3.2 Market Share by Application
7. Market Dynamics
7.1 Industry Trends & Challenges
7.1.1 Mergers & Acquisitions
7.1.2 Automated Blood Component Preparation
7.1.3 Technological Advancement
7.2 Growth Drivers
7.2.1 Rising Demand for Blood Transfusion
7.2.2 Prevalence of Blood Disorders
7.2.3 Increasing Geriatric population
7.2.4 Awareness of Blood Donation
7.2.5 Favorable Government Initiatives
7.3 Challenges
7.3.1 High Risk of Disease Transmission
7.3.2 Regulatory Norms
8. Competitive Landscape
8.1 Market Share Analysis
8.2 Financial Analysis
9. Company Profiles
9.1 GlaxoSmithKline PLC
9.2 Pfizer Inc.
9.3 Baxter Healthcare Corp.
9.4 Bristol-Myers Squibb Co.
9.5 AstraZeneca Co.